Skip to main content

Table 2 Risk factors for overall survival in 4496 patients with limited-disease small-cell lung cancer

From: Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

 

Unadjusted RR

Adjusted RR

 

RR (95% CI)

P-value

RR (95% CI)

P-value

Age, years (≥65 vs. < 65)

1.15 (1.11–1.20)

<  0.0001

1.18 (1.12–1.22)

<  0.0001

Sex (male vs. female)

1.06 (1–1.12)

0.07

1.04 (0.98–1.10)

0.22

HBP (HBP vs. normal)

0.96 (0.93–1.00)

0.05

1.02 (0.98–1.06)

0.45

DM (DM vs. normal)

0.97 (0.93–1.02)

0.22

1.04 (1.00–1.09)

0.06

Hypercholesterolemia (No vs. yes)

1.28 (1.23–1.33)

<  0.0001

1.32 (1.27–1.37)

< 0.0001

Definite CCRT (IP-CCRT vs. EP-CCRT)

1.61 (1.30–2.04)

< 0.0001

1.49 (1.18–1.92)

< 0.0001

  1. RR, relative risk; CI, confidence interval; HBP, hypertension; DM, diabetes mellitus; CCRT, concurrent chemoradiotherapy; IP, irinotecan/platinum; EP, etoposide/platinum